Injectable Fibrous Scaffolds for Meniscal Repair

用于半月板修复的可注射纤维支架

基本信息

批准号：
10670868
负责人：
Karen Xu
金额：
$ 3.5万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-01 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10670868
关键词：
Address Adolescent Adult Animal Model Animals Biocompatible Materials Biological Assay Bypass Cartilage Cell Nucleus Cells Chemotactic Factors Child Clinical Conceptions Cues Defect Degenerative polyarthritis Dense Connective Tissue Deposition Development Electrospinning Engineering Environment Enzymes Excision Exhibits Extracellular Matrix Family suidae Fellowship Fiber Formulation Future Goals Hyaluronic Acid Implant In Situ In Vitro Incidence Individual Infiltration Injectable Injections Injury Investigation Kinetics Knee Light Meniscus structure of joint Miniature Swine Modeling Nuclear Nude Rats Operative Surgical Procedures Pain Patients Physicians Pilot Projects Population Porosity Procedures Process Property Rattus Rehabilitation therapy Research Scientist Site Structure Surgical sutures System Technology Therapeutic Thinness Time Tissue Engineering Tissues Translating Trichostatin A Weight-Bearing state Work aged alternative treatment articular cartilage career cartilage degradation cell motility clinical application comparison control connective tissue growth factor density design efficacy evaluation fabrication fetal healing improved in vivo in vivo Model innovation meniscal tear migration novel strategies pre-clinical recruit release factor repaired response scaffold skills subcutaneous therapeutic development tissue regeneration translational framework wound

项目摘要

Project Summary/Abstract The meniscus is an important load-bearing structure that protects the underlying articular cartilage and thus reduces the incidence of osteoarthritis (OA). Unfortunately, it has limited healing capacity in adults, so tears often require surgical treatment. Current treatments include partial meniscectomy; however, removing part of the meniscus exposes the cartilage and the extent of removal correlates with the magnitude of cartilage degeneration. Unlike adult menisci, fetal and juvenile menisci exhibit intrinsic repair, which reduces the rate at which children present with meniscus tears. Thus, tissue engineering approaches that recapitulate features of younger menisci may provide novel approaches to treating meniscus tears. Multi-fiber scaffolds, whose porosities are tailored to mimic low density fetal extracellular matrices (ECM), have previously been developed that deliver multiple factors to promote initial healing. However, these rigid electrospun scaffolds have reduced control over individual fiber components and cannot be delivered arthroscopically. This proposal targets these impediments by utilizing a post-processing strategy in which a scaffold is fabricated out of fragmented fibers that can be injected into a defect, reconstructed after injection, and stabilized with light. By combining different fiber populations, this assembly permits the individual tuning of various released factors by way of tuning different fiber degradation rates. The proposed scaffold will release a nuclear softening agent (Trichostatin A ‘TSA’) over several days, further mimicking the softer nuclei of fetal menisci compared to adult, and a chemotactic agent (connective tissue growth factor, CTGF) over several weeks. These two factors are expected to synergistically promote cell infiltration and ECM deposition into the scaffold. To demonstrate the translational capacity of this material, three Aims will be conducted. Aim 1 will be geared towards fabricating the material and demonstrating scaffold biofactor release activity individually and when released simultaneously in vitro. Scaffold fiber components will be tailored to have precisely tuned kinetics. Aim 2A will demonstrate the efficacy of the developed fragmented multi-fiber assembly (FMA) in a subcutaneous rat model, thus confirming that the factors released continue to promote cell migration and ECM deposition within an in vivo environment. Aim 2B will involve insertion of the FMA into a meniscus defect site in Yucatan minipigs. This large animal pilot study will demonstrate that the designed material stays within its injection site and that it integrates with the surrounding meniscus on a cellular level. Thus, this sub-Aim will set the framework for future studies assessing the efficacy of this and other proposed tissue engineering approaches in a large animal model of meniscus tears. Successful completion of these Aims will bypass current impediments to implementing fibrous scaffolds clinically, thus providing an alternative treatment option for repairing the meniscus.

项目概要/摘要半月板是重要的承重结构，可以保护下面的关节软骨，从而不幸的是，它对成年人的治愈能力有限，所以眼泪通常需要手术治疗，但目前的治疗方法包括部分半月板切除术；半月板暴露软骨，去除的程度与软骨的大小相关与成人半月板变性不同，胎儿和青少年半月板表现出内在修复，这降低了退化率。因此，组织工程方法概括了半月板撕裂的特征。年轻的半月板可能提供治疗半月板撕裂的新方法，其孔隙度是为了模仿低密度胎儿细胞外基质（ECM）而设计的，之前已经开发出来然而，这些刚性电纺支架已经减少了。该提案针对的是单个纤维成分的控制，并且无法通过关节镜进行递送。通过利用后处理策略来克服障碍，其中支架是由碎片纤维制成的可以注射到缺损处，注射后重建，并通过组合不同的光来稳定。纤维群体，该组件允许通过调节的方式单独调节各种释放的因子不同的纤维降解率。所提出的支架将释放核软化剂（曲古抑菌素A）。 “TSA”）经过几天的时间，进一步模仿了与成人相比胎儿半月板更软的核，并且趋化剂（结缔组织生长因子，CTGF）数周内这两个因素是。预期协同促进细胞浸润和 ECM 沉积到支架中。该材料的转化能力，将实现三个目标 1 将面向制造。材料并展示支架生物因子单独释放活性以及释放时的活性同时在体外，支架纤维组件将被定制以具有精确调整的动力学。证明了所开发的碎片多纤维组件（FMA）在皮下大鼠中的功效模型，从而证实释放的因子继续促进细胞迁移和 ECM 沉积目标 2B 将涉及将 FMA 插入尤卡坦半岛的半月板缺损部位。这项大型动物试点研究将证明设计的材料保留在其注射部位内。并且它在细胞水平上与周围的半月板整合，因此，该子目标将设定评估该方法和其他拟议的组织工程方法的有效性的未来研究框架在半月板撕裂的大型动物模型中，成功完成这些目标将绕过当前的目标。解决了临床上实施纤维支架的障碍，从而为以下疾病提供了替代治疗选择修复半月板。